On Thursday, Cantor Fitzgerald reiterated its Overweight rating on shares of ORIC Pharmaceuticals (NASDAQ: ORIC), currently trading at $5.97, following the company’s announcement of promising ...

Cantor Fitzgerald analyst Prakhar Agrawal commented on the results, stating, "Overall, a solid update by ORIC with not much to nitpick on efficacy/safety." Agrawal reiterated an Overweight rating on ...

Shares of ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) jumped 20% following the release of early data from its ongoing Phase 1b ...

Detailed price information for Oric Pharmaceuticals Inc (ORIC-Q) from The Globe and Mail including charting and trades.

On Thursday, Cantor Fitzgerald reiterated its Overweight rating on shares of ORIC Pharmaceuticals (NASDAQ: ORIC), currently trading at $5.97, following the company’s announcement of promising Phase 1 ...

Cantor Fitzgerald, a financial services firm, that it entered into a definitive agreement to acquire UBS’s O’Connor ...

The global investment platform of financial services firm Cantor Fitzgerald is launching a new product that will allow ...

The Cantor Fitzgerald Gold Protected Bitcoin Fund, which the firm said will be its first BTC-focused investment vehicle, is ...